Crescent Biopharma Inc
F:C68
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Crescent Biopharma Inc
F:C68
|
US |
|
P
|
Publicis Groupe SA
DUS:PU4
|
FR |
|
V
|
Vinci SA
XMUN:SQU
|
FR |
|
G
|
Glencore PLC
XHAM:8GC
|
CH |
|
Compagnie Generale des Etablissements Michelin SCA
PAR:ML
|
FR |
|
D
|
Duke Energy Corp
DUS:D2MN
|
US |
|
E
|
Expeditors International of Washington Inc
XBER:EW1
|
US |
|
Qube Holdings Ltd
ASX:QUB
|
AU |
|
Shimano Inc
F:SHM
|
JP |
|
P
|
Priority Technology Holdings Inc
F:60W
|
US |
|
F
|
Freeport-McMoRan Inc
DUS:FPMB
|
US |
|
Royal Bank of Canada
TSX:RY
|
CA |
Wall St Price Targets
C68 Price Targets Summary
Crescent Biopharma Inc
According to Wall Street analysts, the average 1-year price target for
C68 is 18.09 EUR with a low forecast of 15.6 EUR and a high forecast of 21.03 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is C68's stock price target?
Price Target
18.09
EUR
According to Wall Street analysts, the average 1-year price target for
C68 is 18.09 EUR with a low forecast of 15.6 EUR and a high forecast of 21.03 EUR.
What is the Revenue forecast for Crescent Biopharma Inc?
Projected CAGR
-14%
Over the last 13 years, the compound annual growth rate for Revenue has been -3%. The projected CAGR for the next 3 years is -14%.